Contribution of C3d-P28 repeats to enhancement of immune responses against HBV-preS2/S induced by gene immunization

World Journal of Gastroenterology

Volumn 10, Issue 14, 2004, Pages 2072-2077

  Wang, Li Xin ^a,b   Xu, Wei ^a   Guan, Qing Dong ^a   Chu, Yi Wei ^a   Wang, Ying ^a   Xiong, Si Dong ^a  

^a FUDAN UNIVERSITY   (China)

^b SOUTHEAST UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

COMPLEMENT COMPONENT C3; DNA VACCINE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN; IMMUNOGLOBULIN G; PLASMID DNA; PROTEIN P28; RESTRICTION ENDONUCLEASE; VIRUS DNA; VIRUS FUSION PROTEIN; COMPLEMENT COMPONENT C3D; COMPLEMENT COMPONENT C3D RECEPTOR; HYBRID PROTEIN; PEPTIDE; PRESURFACE PROTEIN 2, HEPATITIS B SURFACE ANTIGEN; PROTEIN PRECURSOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; CONTROLLED STUDY; DNA SEQUENCE; ENZYME LINKED IMMUNOSORBENT ASSAY; EUKARYOTE; EXPRESSION VECTOR; FEMALE; GENE AMPLIFICATION; GENE EXPRESSION; GENETIC CODE; HEPATITIS B VIRUS; HUMAN; HUMAN CELL; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGLOBULIN BLOOD LEVEL; INJECTION; INOCULATION; MOUSE; MOUSE STRAIN; NONHUMAN; POLYMERASE CHAIN REACTION; RECOMBINANT PLASMID; STATISTICAL SIGNIFICANCE; VARIABLE NUMBER OF TANDEM REPEAT; ANIMAL; ANTIBODY PRODUCTION; BAGG ALBINO MOUSE; BINDING SITE; GENE DOSAGE; GENETICS; IMMUNOLOGY; METABOLISM; SYNTHESIS; TUMOR CELL LINE;

ANIMALS; ANTIBODY FORMATION; BINDING SITES; CELL LINE, TUMOR; COMPLEMENT C3D; FEMALE; GENE DOSAGE; HEPATITIS B SURFACE ANTIGENS; HUMANS; IMMUNIZATION; MICE; MICE, INBRED BALB C; PEPTIDES; PROTEIN PRECURSORS; RECEPTORS, COMPLEMENT 3D; RECOMBINANT FUSION PROTEINS;

EID: 4043163989     PISSN: 10079327     EISSN: None     Source Type: Journal    
DOI: 10.3748/wjg.v10.i14.2072     Document Type: Article

References (31)

1. Pepys MB. Role of complement in induction of antibody production in vivo. Effect of cobra venom factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody responses. J Exp Med 1974; 140: 126-145
2. Dempsey PW, Allison MED, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a molecular adjuvant: bridging innate and acquired immunity. Science 1996; 271: 348-350
3. Test ST, Mitsuyoshi J, Connelly CC, Lucas AH. Increased immunogenicity and induction of class switching by conjugation of complement C3d to pneumococcal serotype 14 capsular polysaccharide. Infect Immun 2001; 69: 3031-3040
4. Ross TM, Xu Y, Bright RA, Robinson HL. C3d enhancement of antibodies to Hemagglutinin accelerates protection against influenza virus challenge. Nat Immunol 2000; 1: 127-131
5. Mitchell JA, Green TD, Bright RA, Ross TM. Induction of heterosubtypic immunity to influenza A virus using a DNA vaccine expressing hemagglutinin-C3d fusion proteins. Vaccine 2003; 21: 902-914
6. Ross TM, Xu Y, Green TD, Montefiori DC, Robinson HL. Enhanced avidity maturation of antibody to human immunodeficiency virus envelope: DNA vaccination with gp120-C3d fusion proteins. AIDS Res Hum Retroviruses 2001; 17: 829-835
7. Green TD, Newton BP, Rota PA, Xu Y, Robinson HL, Ross TM. C3d enhancement of neutralizing antibodies to measles hemagglutinin. Vaccine 2001; 20: 242-248
8. Tew JG, Wu J, Qin D, Helm S, Burton GF, Szakal AK. Follicular dendritic cells and presentation of antigen and costimulatory signals to B cells. Immunol Rev 1997; 156: 39-52
9. Yellin MJ, Sinning J, Covey LR, Sherman W, Lee JJ, Glickman-Nir E, Sippel KC, Rogers J, Cleary AM, Parker M, Chess L, Lederman S. T lymphocyte T cell-B cell-activating molecule/CD40-L molecules induce normal B cells or chronic lymphocytic leukemia B cells to express CD80 (B7/BB-1) and enhance their costimulatory activity. J Immunol 1994; 153: 666-674
10. Lambris JD, Ganu VS, Hirani S, Müller-Eberhard HJ. Mapping of the C3d receptor (CR2)-binding site and a neoantigenic site in the C3d domain of the third component of complement. Proc Natl Acad Sci U S A 1985; 82: 4235-4239
11. Esparza I, Becherer JD, Alsenz J, De la Hera A, Lao Z, Tsoukas CD, Lambris JD. Evidence for multiple sites of interaction in C3 for complement receptor type 2 (C3d/EBV receptor, CD21). Eur J Immunol 1991; 21: 2829-2838
12. Servis C, Lambris JD. C3 synthetic peptides support growth of human CR2-positive lymphoblastoid B cells. J Immunol 1989; 142: 2207-2212
13. Frade R, Hermann J, Barel M. A 16 amino acid synthetic peptide derived from human C3d triggers proliferation and specific tyrosine phosphorylation of transformed CR2-positive human lymphocytes and of normal resting lymphocytes-B. Biochem Biophys Res Commun 1992; 188: 833-842
14. Sarrias MR, Franchini S, Canziani G, Argyropoulos E, Moore WT, Sahu A, Lambris JD. Kinetic analysis of the interactions of complement receptor 2 (CR2, CD21) with its ligands C3d, iC3b, and the EBV glycoprotein gp350/220. J Immunol 2001; 167: 1490-1499
15. Lou D, Kohler H. Enhanced molecular mimicry of CEA using photoaffinity crosslinked C3d peptide. Nat Biotechnol 1998; 16: 458-462
16. Chow YH, Chiang BL, Lee YL, Chi WK, Lin WC, Chen YT, Tao MH. Development of Th1 and Th2 populations and the nature of immune responses to hepatitis B virus DNA vaccines can be modulated by codelivery of various cytokine genes. J Immunol 1998; 160: 1320-1329
17. Rottinghaus ST, Poland GA, Jacobson RM, Barr LJ, Roy MJ. Hepatitis B DNA vaccine induces protective antibody responses in human non-responders to conventional vaccination. Vaccine 2003; 31: 4604-4608
18. Kim SJ, Suh D, Park SE, Park JS, Byun HM, Lee C, Lee SY, Kim I, Oh YK. Enhanced immunogenicity of DNA fusion vaccine encoding secreted hepatitis B surface antigen and chemokine RANTES. Virology 2003; 1: 84-91
19. Davis HL, Mancini M, Michel ML, Whalen RG. DNA-mediated immunization to hepatitis B surface antigen: longevity of primary response and effect of boost. Vaccine 1996; 14: 910-915
20. Mancini M, Hadchouel M, Davis HL, Whalen RG, Tiollais P, Michel ML. DNA-mediated immunization in a transgenic mouse model of the hepatitis B surface antigen chronic carrier state. Proc Natl Acad Sci U S A 1996; 93: 12496-12501
21. Hassett DE, Whitton JL. DNA immunization. Trends Microbiol 1996; 4: 307-312
22. Robinson HL, Pertmer TM. DNA vaccines for viral infections: basic studies and applications. Adv Virus Res 2000; 55: 1-74
23. Suradhat S, Braun RP, Lewis PJ, Babiuk LA, Little-van den Hurk SD, Griebel PJ, Abca-Estrada ME. Fusion of C3d molecule with bovine rotavirus VP7 or bovine herpesvirus type 1 glycoprotein D inhibits immune responses following DNA immunization. Vet Immunol Immunopathol 2001; 83: 79-92
24. Davis HL, Brazolot Millan CL. DNA-based immunization against hepatitis B virus. Springer Semin Immunopathol 1997; 19: 195-209
25. Jilg W. Novel hepatitis B vaccines. Vaccine 1998; 16: S65-S68
26. Berek C, Berger A, Apel M. Maturation of the immune response in germinal centers. Cell 1991; 67: 1121-1129
27. Jacob J, Kelsoe G, Rajewsky K, Weiss U. Intraclonal generation of antibody mutants in germinal centres. Nature 1991; 354: 389-392
28. Fang Y, Xu C, Fu YX, Holers VM, Molina H. Expression of complement receptors 1 and 2 on follicular dendritic cells is necessary for the generation of a strong antigen-specific IgG response. J Immunol 1998; 160: 5273-5279
29. Griffioen AW, Rijkers GT, Janssens-Korpela P, Zegers BJM. Pneumococcal polysaccharides complexed with C3d bind to human B lymphocytes via complement receptor type 2. Infect Immun 1991; 59: 1839-1845
30. Razanajaona D, van Kooten C, Lebecque S, Bridon JM, Ho S, Smith S, Callard R, Banchereau J, Briere F. Somatic mutations in human Ig variable genes correlate with a partially functional CD40-ligand in the X-linked hyper-IgM syndrome. J Immunol 1996; 157: 1492-14928
31. Fischer MB, Goerg S, Shen L, Prodeus AP, Goodnow CC, Kelsoe G, Carroll MC. Dependence of germinal center B cells on expression of CD21/CD35 for survival. Science 1998; 280: 582-585